Concise Prescribing Info
Belantamab mafodotin
Monotherapy for the treatment of multiple myeloma in adults, who have received at least 4 prior therapies & whose disease is refractory to at least 1 proteasome inhibitor, 1 immunomodulatory agent, & an anti-CD38 monoclonal Ab, & who have demonstrated disease progression on the last therapy.
Dosage/Direction for Use
IV 2.5 mg/kg infused over 30 min once every 3 wk.
Special Precautions
Reports of corneal adverse reactions. Perform ophth examination (including visual acuity & slit lamp examination) at baseline, before the subsequent 3 treatment cycles, & as clinically indicated during treatment. Administer preservative-free artificial tears at least 4 times daily beginning on the 1st day of infusion & continuing until completion of treatment to reduce corneal symptoms. Avoid using contact lenses until the end of treatment. Reports of thrombocytopenic events. Obtain complete blood counts at baseline & monitor during treatment, as clinically indicated. Reports of infusion-related reactions. Moderate influence on the ability to drive or use machines. Patients w/ severe renal impairment. Patients w/ moderate or severe hepatic impairment. May impair fertility in females & males of reproductive potential. Women of child-bearing potential should use effective contraception during treatment & for 4 mth after the last dose. Men w/ female partners of child-bearing potential should use effective contraception during treatment & for 6 mth after the last dose. Pregnancy. Discontinue breast-feeding prior to initiating treatment & for 3 mth after the last dose. Childn & adolescents <18 yr. Patients w/ body wt <40 or >130 kg.
Adverse Reactions
Pneumonia; thrombocytopenia, anaemia, lymphopenia, leukopenia, neutropenia; keratopathy, blurred vision events, dry eye events; nausea, diarrhoea; pyrexia, fatigue; increased AST & γ-glutamyltransferase; infusion-related reactions. Upper resp tract infection; photophobia, eye irritation; vomiting; increased creatine phosphokinase.
MIMS Class
Targeted Cancer Therapy
ATC Classification
L01FX15 - belantamab mafodotin ; Belongs to the class of other monoclonal antibodies and antibody drug conjugates. Used in the treatment of cancer.
Blenrep powd for concentrate for soln for infusion 100 mg
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $768 a year.
Sign up for free
Already a member? Sign in